首站-论文投稿智能助手
典型文献
Inhibition of temperature-sensitive TRPV3 channel by two natural isochlorogenic acid isomers for alleviation of dermatitis and chronic pruritus
文献摘要:
Genetic gain-of-function mutations of warm temperature-sensitive transient receptor poten-tial vanilloid 3(TRPV3)channel cause Olmsted syndrome characterized by severe itching and keratoder-ma,indicating that pharmacological inhibition of TRPV3 may hold promise for therapy of chronic pruritus and skin diseases.However,currently available TRPV3 tool inhibitors are either nonselective or less potent,thus impeding the validation of TRPV3 as therapeutic target.Using whole-cell patch-clamp and single-channel recordings,we report the identification of two natural dicaffeoylquinic acid isomers isochlorogenic acid A(IAA)and isochlorogenic acid B(IAB)that selectively inhibit TRPV3 currents with IC50 values of 2.7±1.3 and 0.9±0.3 μmol/L,respectively,and reduce the channel open probability to 3.7±1.2%and 3.2±1.1%from 26.9±5.5%,respectively.In vivo evaluation confirms that both IAA and IAB significantly reverse the ear swelling of dermatitis and chronic pruritus.Furthermore,the isomer IAB is able to rescue the keratinocyte death induced by TRPV3 agonist carvacrol.Molecular docking combined with site-directed mutations reveals two residues T636 and F666 critical for the binding of the two isomers.Taken together,our identification of isochlorogenic acids A and B that act as specific TRPV3 channel inhibitors and gating modifiers not only provides an essential pharmacological tool for further investigation of the channel pharmacology and pathology,but also holds developmental potential for treatment of dermatitis and chronic pruritus.
文献关键词:
作者姓名:
Hang Qi;Yuntao Shi;Han Wu;Canyang Niu;Xiaoying Sun;KeWei Wang
作者机构:
Department of Pharmacology,School of Pharmacy,Qingdao University,Qingdao 266021,China;State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China;Institue of Innovative Drugs,Qingdao University,Qingdao 266021,China
引用格式:
[1]Hang Qi;Yuntao Shi;Han Wu;Canyang Niu;Xiaoying Sun;KeWei Wang-.Inhibition of temperature-sensitive TRPV3 channel by two natural isochlorogenic acid isomers for alleviation of dermatitis and chronic pruritus)[J].药学学报(英文版),2022(02):723-734
A类:
Olmsted,keratoder,T636,F666
B类:
Inhibition,temperature,sensitive,TRPV3,channel,by,two,natural,isochlorogenic,isomers,alleviation,dermatitis,chronic,pruritus,Genetic,gain,function,mutations,warm,transient,receptor,vanilloid,cause,syndrome,characterized,severe,itching,indicating,that,pharmacological,inhibition,may,promise,therapy,skin,diseases,However,currently,available,tool,inhibitors,are,either,nonselective,less,thus,impeding,validation,therapeutic,target,Using,whole,cell,patch,clamp,single,recordings,report,identification,dicaffeoylquinic,IAA,IAB,selectively,currents,IC50,values,respectively,reduce,open,probability,from,vivo,evaluation,confirms,both,significantly,reverse,ear,swelling,Furthermore,rescue,keratinocyte,death,induced,agonist,carvacrol,Molecular,docking,combined,site,directed,reveals,residues,critical,binding,Taken,together,our,acids,specific,gating,modifiers,not,only,provides,essential,further,investigation,pharmacology,pathology,but,also,holds,developmental,potential,treatment
AB值:
0.546693
相似文献
Vanilloid agonist-mediated activation of TRPV1 channels requires coordinated movement of the S1-S4 bundle rather than a quiescent state
Meng-Yang Sun;Xue Zhang;Peng-Cheng Yu;Di Liu;Yang Yang;Wen-Wen Cui;Xiao-Na Yang;Yun-Tao Lei;Xing-Hua Li;Wen-Hui Wang;Peng Cao;Heng-Shan Wang;Michael X.Zhu;Chang-Zhu Li;Rui Wang;Ying-Zhe Fan;Ye Yu-School of Life Sciences and Key Laboratory of Preclinical Study for New Drugs of Gansu Province,School of Basic Medical Sciences,Lanzhou University,Lanzhou 730000,China;Department of Pharmacology and Chemical Biology,Institute of Medical Sciences,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Department of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing 210009,China;College of Bioscience and Biotechnology,Hunan Agricultural University,Changsha 410128,China;Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine,Nanjing 210023,China;State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources,Collaborative Innovation Center for Guangxi Ethnic Medicine,School of Chemistry and Pharmaceutical Sciences,Guangxi Normal University,Guilin 541004,China;Department of Integrative Biology and Pharmacology,McGovern Medical School,The University of Texas Health Science Center at Houston,Houston,TX 77030,USA;State Key Laboratory of Utilization of Woody Oil Resource,Hunan Academy of Forestry,Changsha 410004,China;Putuo Hospital,Shanghai University of Chinese Traditional Medicine,Shanghai 200062,China
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Huan Ma;Xinghai Zhang;Peiyi Zheng;Peter H.Dube;Weihong Zeng;Shaohong Chen;Qingyu Cheng;Yunru Yang;Yan Wu;Junhui Zhou;Xiaowen Hu;Yan Xiang;Huajun Zhang;Sandra Chiu;Tengchuan Jin-Department of Pulmonary and Critical Care Medicine,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,Hubei,China;Laboratory of Structural Immunology,CAS Key Laboratory of Innate Immunity and Chronic Disease,Hefei National Laboratory for Physical Sciences at Microscale,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;Department of Microbiology,Immunology and Molecular Genetics,University of Texas Health Science Center at San Antonio,San Antonio,TX,USA;University of Chinese Academy of Sciences,Beijing,China;Institute of Health and Medicine,Hefei Comprehensive National Science Center,Hefei,Anhui,China
Chalcone derivatives ameliorate lipopolysaccharide-induced acute lung injury and inflammation by targeting MD2
Ya-li Zhang;Wen-xin Zhang;Jue-qian Yan;Ye-lin Tang;Wen-jing Jia;Zheng-wei Xu;Ming-jiang Xu;Nipon Chattipakorn;Yi Wang;Jian-peng Feng;Zhi-guo Liu;Guang Liang-Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325035,China;Key Laboratory of Molecular Pharmacology and Drug Evaluation(Yantai University),Ministry of Education,Yantai University,Yantai 264005,China;School of Pharmaceutical Sciences,Hangzhou Medical College,Hangzhou 311399,China;Zhuji Biomedicine Institute,School of Pharmaceutical Sciences,Wenzhou Medical University,Zhuji 311800,China;Cardiac Electrophysiology Research and Training Center,Faculty of Medicine,Chiang Mai University,Chiang Mai 50200,Thailand;Wenzhou Institute,University of Chinese Academy of Sciences,Wenzhou 325001,China
Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates
Yi Wang;Sui Fang;Yan Wu;Xi Cheng;Lei-ke Zhang;Xu-rui Shen;Shuang-qu Li;Jian-rong Xu;Wei-juan Shang;Zhao-bing Gao;Bing-qing Xia-CAS Key Laboratory of Receptor Research,Stake Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan 430071,China;Academy of Integrative Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of Pharmacology and Chemical Biology,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Zhongshan Institute of Drug Discovery,Institution for Drug Discovery Innovation,Chinese Academy of Science,Zhongshan 528400,China
Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis
Ying Dong;Bi-xi Tang;Qi Wang;Li-wei Zhou;Cong Li;Xuan Zhang;Dan-dan Sun;Xin Sun;Xue-mei Zhang;Bing Xiong;Jia Li;Hong Shi;Dan-qi Chen;Yi Zang-State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Department of Pharmacology,School of Pharmacy,Fudan University,Shanghai 201203,China;Department of Medicinal Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Center for Supramolecular Chemistry and Catalysis and Department of Chemistry,College of Sciences,Shanghai University,Shanghai 200444,China;Schoolof Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing 210023,China;Schoolof Pharmacy,Henan University,Kaifeng 475004,China;Open Studio for Druggability Research of Marine Natural Products,Pilot National Laboratory for Marine Science and Technology(Qingdao),Qingdao 266237,China;School of Pharmaceutical Science and Technology,Hangzhou Institute for Advanced Study,UCAS,Hangzhou 310024,China;Department of Anesthesiology of Shanghai Pulmonary Hospital,School of medicine,Tongji University,Shanghai 200433,China
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。